Eye Melanoma Market Size, Share Analysis, Industry Insights, Growth, And Forecast To 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2038

The Business Research Company offers in-depth market insights through Eye Melanoma Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The eye melanoma market size has grown strongly in recent years. It will grow from $8.29 billion in 2023 to $9.1 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs..

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $12.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends.. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13109&type=smp

Market Segmentation:
The eye melanoma market covered in this report is segmented -
1) By Site: Uvea, Sclera, Retina
2) By Diagnosis: Imaging, Biopsy, Eye Exam
3) By Treatment: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Other Treatment
4) By End User: Hospitals And Clinics, Academic Institutes

Major Driver - Rising Prevalence Of Eye Cancer Boosts Growth Prospects For The Eye Melanoma Market
The increasing prevalence of eye cancer is expected to propel the growth of the eye melanoma market going forward. Eye cancer refers to the development of abnormal and uncontrolled cell growth within the eye's structures. The growing recognition and effective management of early cases are creating a heightened need for specialized therapies and interventions, propelled by improved detection methods, increased awareness, and advancements in treatment options. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of eye and orbital cancer cases increased to 3,490 in 2023, reflecting a growth of 5.12% from 3,320 in 2021. Therefore, the increasing prevalence of eye cancer will drive the growth of the eye melanoma market.

Competitive Landscape:
Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc , Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd, IDEAYA Biosciences, Immunocore Limited , Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Top Trend - Pioneering Advances In Eye Melanoma Treatment For Unresectable Or Metastatic Uveal Melanoma
Major companies operating in the eye melanoma treatment sector are focused on developing innovative and specialized treatments, such as immunotherapies and targeted therapies, to enhance patient outcomes and quality of life. Immunotherapies and targeted therapies are novel treatment modalities that have recently begun to enter the oncology field. For instance, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical company that focuses on research and development of biological drugs using soluble T-cell receptor technology, received approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn), a T-cell receptor therapeutic, which is the first therapy for individuals with unresectable or metastatic uveal melanoma (mUM). Kimmtrak is an immunotherapy that targets a specific protein called gp100, which is present on the surface of uveal melanoma (UM) cells. It activates the patient's immune system to eliminate melanoma by engaging specialized immune cells through engineered T-cell receptors, offering a precision-driven approach to cancer treatment.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Eye Melanoma Market Characteristics
3. Eye Melanoma Market Trends And Strategies
4. Eye Melanoma Market - Macro Economic Scenario
5. Eye Melanoma Market Size And Growth
…..
27. Eye Melanoma Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

This release was published on openPR.